Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024)
Avalo Therapeutics' (AVTX) quarterly Gross Margin came in at 186.75% in Q3 2024, down 18209.0% YoY from N/an in Q4 2023, and down 234.64% on a QoQ basis from 138.7% in Q4 2023.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024) Analysis & Trends
Avalo Therapeutics (AVTX) has 8 years of Gross Margin data on file, last reported at 186.75% in Q3 2024.
- Quarterly Gross Margin fell 18209.0% year-over-year to 186.75% in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 11.71% (down 1722.0% YoY) and the FY2023 annual result came in at 33.26%, down 4771.0% from the prior year.
- Gross Margin declined to 186.75% in Q3 2024, from 138.7% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 138.7% in Q4 2023 to a low of 186.75% in Q3 2024.
- A 5-year average of 31.49% and a median of 38.62% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2021 — Gross Margin slumped 18833 bps — and 2022, when it soared 12441 bps.
- Tracing AVTX's Gross Margin over 5 years: stood at 94.72% in 2020, then slumped by 199 bps to 93.61% in 2021, then jumped by 133 bps to 30.8% in 2022, then soared by 350 bps to 138.7% in 2023, then plunged by 235 bps to 186.75% in 2024.
- The last three Gross Margin figures came in at 186.75% (Q3 2024), 138.7% (Q4 2023), and 4.66% (Q3 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -186.75% |
| Dec 31, 2023 | 138.70% |
| Sep 30, 2023 | -4.66% |
| Jun 30, 2023 | -10.11% |
| Mar 31, 2023 | -16.00% |
| Dec 31, 2022 | 30.80% |
| Sep 30, 2022 | 96.47% |
| Jun 30, 2022 | -51.69% |
| Mar 31, 2022 | 38.62% |
| Dec 31, 2021 | -93.61% |
| Sep 30, 2021 | 32.74% |
| Jun 30, 2021 | 97.53% |
| Mar 31, 2021 | 83.72% |
| Dec 31, 2020 | 94.72% |
| Sep 30, 2020 | 93.07% |
| Jun 30, 2020 | 94.17% |
| Mar 31, 2020 | 97.60% |
| Dec 31, 2019 | 560.50% |
| Sep 30, 2019 | 93.99% |
| Jun 30, 2019 | -6.91% |